ARTICLE IN PRESS a r c h s o c e s p o f t a l m o l . 2 0 1 6; x x x(x x) :xxx–xxx www . elsevier.es/oftalmologia ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA Original article Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction  L. García-Pérez a,b,c,d , R. Abreu-González e , J. Pérez-Ramos a,b,c,d , S. García-Pérez c,f , P. Serrano-Aguilar a,c,d,* a Servicio de Evaluación, Servicio Canario de la Salud (SESCS), Tenerife, Spain b Fundación Canaria de Investigación Sanitaria (FUNCANIS), Tenerife, Spain c Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain d Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Universidad de La Laguna, La Laguna, Spain e Servicio de Oftalmología, Hospital Universitario Nuestra Se ˜ nora de La Candelaria, Tenerife, Spain f Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain a r t i c l e i n f o Article history: Received 21 May 2015 Accepted 15 January 2016 Available online xxx Keywords: Vitreomacular traction Ocriplasmin Cost-effectiveness Systematic review Economic impact a b s t r a c t Objective: To review the evidence on the cost-effectiveness of ocriplasmin as a treatment for vitreomacular traction (VMT), and to estimate the impact on the Spanish National Health System (NHS). Material and methods: (1) Systematic review. The following databases were searched in Jan- uary 2015: MEDLINE, PREMEDLINE, EMBASE, CRD, the Cochrane Library, and key websites. Selection criteria were: full economic evaluations that compared ocriplasmin with usual care (‘watch and wait’ and/or vitrectomy) in patients with VMT. The outcomes to extract were costs of the alternatives and the incremental cost-effectiveness ratio. Studies of bud- get impact analysis were also included. The methodological quality was assessed, and a narrative synthesis of the included studies was carried out. (2) Estimation of budget impact. The impact on the budget as a result of the introduction of ocriplasmin in the NHS was estimated, including data from different sources. Results: Six studies were identified, none of them performed in Spain. The two best studies concluded that ocriplasmin is cost-effective in their respective countries (Canada and United Kingdom), but only in patients with certain conditions (without epiretinal membrane, for example). The results of the budget impact analysis are different between countries. The analysis for Spain showed that the introduction of ocriplasmin would mean a saving over 1 million Euros for the NHS in 5 years.  Please cite this article as: García-Pérez L, Abreu-González R, Pérez-Ramos J, García-Pérez S, Serrano-Aguilar P. Revisión de estudios económicos y análisis de impacto presupuestario de la ocriplasmina como tratamiento de la tracción vitreomacular. Arch Soc Esp Oftalmol. 2016. http://dx.doi.org/10.1016/j.oftal.2016.01.022 ∗ Corresponding author. E-mail addresses: lidia.garciaperez@sescs.es (L. García-Pérez), pseragu@gobiernodecanarias.org (P. Serrano-Aguilar). 2173-5794/© 2016 Sociedad Espa ˜ nola de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved. OFTALE-971; No. of Pages 8